midazolam has been researched along with Liver Steatosis in 3 studies
Midazolam: A short-acting hypnotic-sedative drug with anxiolytic and amnestic properties. It is used in dentistry, cardiac surgery, endoscopic procedures, as preanesthetic medication, and as an adjunct to local anesthesia. The short duration and cardiorespiratory stability makes it useful in poor-risk, elderly, and cardiac patients. It is water-soluble at pH less than 4 and lipid-soluble at physiological pH.
midazolam : An imidazobenzodiazepine that is 4H-imidazo[1,5-a][1,4]benzodiazepine which is substituted by a methyl, 2-fluorophenyl and chloro groups at positions 1, 6 and 8, respectively.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Propofol is a widely used rapidly acting sedating or hypnotic agent in the intensive care setting." | 5.35 | Isolated fatty liver from prolonged propofol use in a pediatric patient with refractory status epilepticus. ( Ko, DY; Rison, RA, 2009) |
| "Caffeine elimination was accelerated by microvesicular steatosis, whereas midazolam elimination was delayed in macrovesicular steatosis." | 1.72 | Periportal steatosis in mice affects distinct parameters of pericentral drug metabolism. ( Albadry, M; Böttcher, M; Christ, B; Christ, M; Dahmen, U; Dirsch, O; Ehteshamzad, N; Höpfl, S; Klopfleisch, R; König, M; Laue, H; Lupp, A; Neumann, J; Radde, N; Schwen, LO, 2022) |
| " An abnormal liver function test likely gives the clinician a hint about dosage adjustment." | 1.42 | Serum alanine transaminase total bilirubin concentrations predict CYP3A activity as measured by midazolam and 1'-hydroxylation. ( He, R; Li, Y; Ruan, J, 2015) |
| "Propofol is a widely used rapidly acting sedating or hypnotic agent in the intensive care setting." | 1.35 | Isolated fatty liver from prolonged propofol use in a pediatric patient with refractory status epilepticus. ( Ko, DY; Rison, RA, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Albadry, M | 2 |
| Höpfl, S | 2 |
| Ehteshamzad, N | 2 |
| König, M | 2 |
| Böttcher, M | 2 |
| Neumann, J | 2 |
| Lupp, A | 2 |
| Dirsch, O | 2 |
| Radde, N | 2 |
| Christ, B | 2 |
| Christ, M | 2 |
| Schwen, LO | 2 |
| Laue, H | 2 |
| Klopfleisch, R | 2 |
| Dahmen, U | 2 |
| He, R | 1 |
| Li, Y | 1 |
| Ruan, J | 1 |
| Rison, RA | 1 |
| Ko, DY | 1 |
3 other studies available for midazolam and Liver Steatosis
| Article | Year |
|---|---|
Periportal steatosis in mice affects distinct parameters of pericentral drug metabolism.
Topics: Animals; Caffeine; Cytochrome P-450 Enzyme System; Fatty Liver; Metabolic Clearance Rate; Mice; Mida | 2022 |
Periportal steatosis in mice affects distinct parameters of pericentral drug metabolism.
Topics: Animals; Caffeine; Cytochrome P-450 Enzyme System; Fatty Liver; Metabolic Clearance Rate; Mice; Mida | 2022 |
Periportal steatosis in mice affects distinct parameters of pericentral drug metabolism.
Topics: Animals; Caffeine; Cytochrome P-450 Enzyme System; Fatty Liver; Metabolic Clearance Rate; Mice; Mida | 2022 |
Periportal steatosis in mice affects distinct parameters of pericentral drug metabolism.
Topics: Animals; Caffeine; Cytochrome P-450 Enzyme System; Fatty Liver; Metabolic Clearance Rate; Mice; Mida | 2022 |
Serum alanine transaminase total bilirubin concentrations predict CYP3A activity as measured by midazolam and 1'-hydroxylation.
Topics: Alanine Transaminase; Analysis of Variance; Bilirubin; Biomarkers; Cytochrome P-450 CYP3A; End Stage | 2015 |
Isolated fatty liver from prolonged propofol use in a pediatric patient with refractory status epilepticus.
Topics: Adolescent; Anticonvulsants; Fatty Liver; Female; Humans; Midazolam; Propofol; Status Epilepticus; T | 2009 |